
Cellectis S.A. – NASDAQ:CLLS
Cellectis S.A. stock price today
Cellectis S.A. stock price monthly change
Cellectis S.A. stock price quarterly change
Cellectis S.A. stock price yearly change
Cellectis S.A. key metrics
Market Cap | 109.55M |
Enterprise value | 67.80M |
P/E | -1.01 |
EV/Sales | 3.07 |
EV/EBITDA | -0.87 |
Price/Sales | 4.08 |
Price/Book | 0.65 |
PEG ratio | 1.97 |
EPS | -1.02 |
Revenue | 5.14M |
EBITDA | -84.11M |
Income | -65.34M |
Revenue Q/Q | 3157.55% |
Revenue Y/Y | -70.98% |
Profit margin | -497.34% |
Oper. margin | -636.4% |
Gross margin | 44.94% |
EBIT margin | -636.4% |
EBITDA margin | -1635.17% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCellectis S.A. stock price history
Cellectis S.A. stock forecast
Cellectis S.A. financial statements
Jun 2023 | 178K | -10.64M | -5982.02% |
---|---|---|---|
Sep 2023 | 155K | -17.48M | -11278.71% |
Dec 2023 | 283K | -42.86M | -15145.58% |
Mar 2024 | 4.52M | 5.64M | 124.62% |
Sep 2025 | 6.59M | -28.86M | -437.83% |
---|---|---|---|
Dec 2025 | 197.25K | -20.94M | -10620.42% |
Dec 2025 | 10.61M | -28.86M | -272.02% |
Mar 2026 | 3.07M | -33.79M | -1097.46% |
Analysts Price target
Financials & Ratios estimates
2022-11-03 | -0.46 | -0.63 |
---|---|---|
2023-03-08 | -0.49029 | -0.59 |
Jun 2023 | 227674000 | 131.11M | 57.59% |
---|---|---|---|
Sep 2023 | 209700000 | 133.57M | 63.7% |
Dec 2023 | 334270000 | 249.57M | 74.66% |
Mar 2024 | 354459000 | 263.89M | 74.45% |
Jun 2023 | -19.04M | -1.78M | 19.81M |
---|---|---|---|
Sep 2023 | -17.09M | -300K | 1.68M |
Dec 2023 | 39.61M | -13.65M | 41.68M |
Mar 2024 | -23.54M | -2.05M | 12.12M |
Cellectis S.A. alternative data
Company's Focus On Multiple Cancers Including
21 May 2023 | 12 | 1 | 7 | 34 |
---|---|---|---|---|
28 May 2023 | 13 | 1 | 8 | 31 |
4 Jun 2023 | 13 | 1 | 15 | 32 |
11 Jun 2023 | 13 | 1 | 6 | 32 |
18 Jun 2023 | 14 | 1 | 6 | 32 |
25 Jun 2023 | 11 | 1 | 6 | 32 |
2 Jul 2023 | 11 | 1 | 6 | 35 |
9 Jul 2023 | 10 | 1 | 6 | 31 |
16 Jul 2023 | 10 | 1 | 5 | 31 |
23 Jul 2023 | 10 | 1 | 6 | 34 |
30 Jul 2023 | 12 | 1 | 7 | 34 |
6 Aug 2023 | 12 | 1 | 6 | 34 |
13 Aug 2023 | 10 | 1 | 6 | 32 |
20 Aug 2023 | 9 | 2 | 6 | 31 |
27 Aug 2023 | 10 | 1 | 6 | 32 |
3 Sep 2023 | 10 | 1 | 6 | 30 |
10 Sep 2023 | 10 | 1 | 6 | 30 |
17 Sep 2023 | 11 | 2 | 6 | 30 |
24 Sep 2023 | 10 | 1 | 6 | 35 |
1 Oct 2023 | 9 | 1 | 6 | 32 |
Gene editing
21 May 2023 | 11 |
---|---|
28 May 2023 | 12 |
4 Jun 2023 | 11 |
11 Jun 2023 | 12 |
18 Jun 2023 | 14 |
25 Jun 2023 | 15 |
2 Jul 2023 | 19 |
9 Jul 2023 | 18 |
16 Jul 2023 | 16 |
23 Jul 2023 | 27 |
30 Jul 2023 | 22 |
6 Aug 2023 | 16 |
13 Aug 2023 | 19 |
20 Aug 2023 | 16 |
27 Aug 2023 | 19 |
3 Sep 2023 | 20 |
10 Sep 2023 | 21 |
17 Sep 2023 | 23 |
24 Sep 2023 | 25 |
1 Oct 2023 | 21 |
Gene Editing Companies
21 May 2023 | 24 | 1 | 4 | 10 | 16 |
---|---|---|---|---|---|
28 May 2023 | 12 | 0 | 3 | 12 | 11 |
4 Jun 2023 | 18 | 0 | 5 | 15 | 4 |
11 Jun 2023 | 21 | 0 | 2 | 12 | 7 |
18 Jun 2023 | 18 | 0 | 5 | 9 | 7 |
25 Jun 2023 | 19 | 0 | 5 | 11 | 7 |
2 Jul 2023 | 16 | 1 | 6 | 21 | 7 |
9 Jul 2023 | 14 | 2 | 2 | 10 | 4 |
16 Jul 2023 | 14 | 0 | 3 | 11 | 9 |
23 Jul 2023 | 37 | 0 | 8 | 15 | 11 |
30 Jul 2023 | 25 | 1 | 7 | 15 | 11 |
6 Aug 2023 | 27 | 0 | 6 | 16 | 7 |
13 Aug 2023 | 21 | 7 | 4 | 10 | 4 |
20 Aug 2023 | 19 | 1 | 4 | 13 | 7 |
27 Aug 2023 | 17 | 0 | 8 | 13 | 8 |
3 Sep 2023 | 19 | 2 | 7 | 19 | 5 |
10 Sep 2023 | 22 | 1 | 5 | 20 | 6 |
17 Sep 2023 | 37 | 0 | 9 | 29 | 11 |
24 Sep 2023 | 47 | 0 | 11 | 31 | 29 |
1 Oct 2023 | 42 | 1 | 11 | 30 | 20 |
Types of gene editing
5 Mar 2023 | 11 | 20 | 0 |
---|---|---|---|
12 Mar 2023 | 12 | 18 | 0 |
19 Mar 2023 | 9 | 19 | 1 |
26 Mar 2023 | 9 | 21 | 0 |
2 Apr 2023 | 9 | 22 | 1 |
9 Apr 2023 | 21 | 31 | 0 |
16 Apr 2023 | 16 | 24 | 1 |
23 Apr 2023 | 13 | 23 | 1 |
30 Apr 2023 | 11 | 21 | 0 |
7 May 2023 | 10 | 61 | 0 |
14 May 2023 | 13 | 37 | 1 |
21 May 2023 | 9 | 30 | 1 |
28 May 2023 | 10 | 29 | 1 |
4 Jun 2023 | 10 | 24 | 1 |
11 Jun 2023 | 10 | 29 | 0 |
18 Jun 2023 | 10 | 29 | 1 |
25 Jun 2023 | 11 | 28 | 1 |
2 Jul 2023 | 9 | 35 | 1 |
9 Jul 2023 | 19 | 39 | 1 |
16 Jul 2023 | 100 | 34 | 0 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
Aug 2023 | 4 |
---|---|
Sep 2023 | 2 |
Oct 2023 | 2 |
Nov 2023 | 1 |
Dec 2023 | 4 |
Jan 2024 | 4 |
Feb 2024 | 4 |
Apr 2024 | 4 |
May 2024 | 15 |
Jun 2024 | 30 |
Jul 2024 | 27 |
Dec 2024 | 9 |
Aug 2023 | 231 |
---|---|
Sep 2023 | 231 |
Oct 2023 | 231 |
Nov 2023 | 231 |
Dec 2023 | 231 |
Jan 2024 | 231 |
Feb 2024 | 231 |
Mar 2024 | 231 |
Apr 2024 | 231 |
May 2024 | 231 |
Jun 2024 | 216 |
Jul 2024 | 216 |
Cellectis S.A. other data
Patent |
---|
Application Filling date: 30 Mar 2018 Issue date: 3 Jun 2021 |
Application Filling date: 30 Mar 2018 Issue date: 8 Apr 2021 |
Application Filling date: 13 Nov 2020 Issue date: 4 Mar 2021 |
Quarter | Transcript |
---|---|
Q1 2024 30 May 2024 | Q1 2024 Earnings Call Transcript |
Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 4 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 5 May 2023 | Q1 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Andre Choulika Ph.D. (1965) Co-Founder, Chief Executive Officer & Director | $1,150,000 |
Dr. David J. D. Sourdive Ph.D. (1967) Co-Founder, Executive Vice President of CMC and Manufacturing & Director | $476,630 |
Cellectis: Poised To Start Answering Questions In 2025
Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024
Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects
Iovance: Rolling BLA Development Signals More Upside
Allogene: Speculative CAR T Biotech With Big Potential In Oncology
MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile
Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential
CRISPR: 4 Emerging Players
Calyxt: Proprietary TALEN Plant-Technology Offers Multi-Industry Growth
-
What's the price of Cellectis S.A. stock today?
One share of Cellectis S.A. stock can currently be purchased for approximately $2.99.
-
When is Cellectis S.A.'s next earnings date?
Unfortunately, Cellectis S.A.'s (CLLS) next earnings date is currently unknown.
-
Does Cellectis S.A. pay dividends?
No, Cellectis S.A. does not pay dividends.
-
How much money does Cellectis S.A. make?
Cellectis S.A. has a market capitalization of 109.55M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 96.06% to 755K US dollars. Cellectis S.A. made a loss 101.06M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.
-
What is Cellectis S.A.'s stock symbol?
Cellectis S.A. is traded on the NASDAQ under the ticker symbol "CLLS".
-
What is Cellectis S.A.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cellectis S.A.?
Shares of Cellectis S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cellectis S.A.'s key executives?
Cellectis S.A.'s management team includes the following people:
- Dr. Andre Choulika Ph.D. Co-Founder, Chief Executive Officer & Director(age: 60, pay: $1,150,000)
- Dr. David J. D. Sourdive Ph.D. Co-Founder, Executive Vice President of CMC and Manufacturing & Director(age: 58, pay: $476,630)
-
Is Cellectis S.A. founder-led company?
Yes, Cellectis S.A. is a company led by its founders Dr. Andre Choulika Ph.D. and Dr. David J. D. Sourdive Ph.D..
-
How many employees does Cellectis S.A. have?
As Jul 2024, Cellectis S.A. employs 216 workers, which is 6% less then previous quarter.
-
When Cellectis S.A. went public?
Cellectis S.A. is publicly traded company for more then 10 years since IPO on 24 Mar 2015.
-
What is Cellectis S.A.'s official website?
The official website for Cellectis S.A. is cellectis.com.
-
How can i contact Cellectis S.A.?
Cellectis S.A. can be reached via phone at +33 1 81 69 16 00.
Cellectis S.A. company profile:

Cellectis S.A.
cellectis.comNASDAQ
216
Biotechnology
Healthcare
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Paris, 75013
CIK: 0001627281
ISIN: US15117K1034
CUSIP: 15117K103